Gazendam A, Popovic S, Parasu N, Ghert M (2023) Chondrosarcoma: a clinical review. J Clin Med 12:2506. https://doi.org/10.3390/jcm12072506

Article  PubMed  PubMed Central  Google Scholar 

Ottesen TD, Shultz BN, Munger AM, Amick M, Toombs CS, Friedaender GE, Grauer JN (2022) Chondrosarcoma patient characteristics, management, and outcomes based on over 5,000 cases from the national cancer database (NCDB). PLoS ONE 17:e0268215. https://doi.org/10.1371/journal.pone.0268215

Article  PubMed  PubMed Central  Google Scholar 

Ylenia Giuffrida A, Giuffrida AY, Burgueno JE, Burgueno JE, Koniaris LG, Koniaris LG, Gutierrez JC, Gutierrez JC, Duncan RC, Duncan R, Scully SP, Scully SP (2009) Chondrosarcoma in the united states (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am 91:1063–1072. https://doi.org/10.2106/jbjs.h.00416

Article  Google Scholar 

Song K, Shi X, Liang X, Wang H, Zou F, Lu F, Ma X, Jiang J (2018) Risk factors for metastasis at presentation with conventional chondrosarcoma: a population-based study. Int Orthop (SICOT) 42:2941–2948. https://doi.org/10.1007/s00264-018-3942-7

Article  Google Scholar 

Abunimer AM, Hammoudeh L, Dee EC, Lak AM, Chi J, Lu Y, Groff M, Shin JH, Lam MB, Zaidi HA (2023) Gross total resection of spinal chondrosarcoma is associated with improved locoregional relapse-free survival and overall survival. Eur Spine J 32:994–1002. https://doi.org/10.1007/s00586-022-07505-3

Article  PubMed  Google Scholar 

Yin H, Zhou W, Meng J, Zhang D, Wu Z, Wang T, Wang J, Wang P, Shi X, Wu S, Zhao J, Xiao J (2014) Prognostic factors of patients with spinal chondrosarcoma: a retrospective analysis of 98 consecutive patients in a single center. Ann Surg Oncol 21:3572–3578. https://doi.org/10.1245/s10434-014-3745-z

Article  PubMed  Google Scholar 

Xu K, Li B, Huang Q, Jiang D, Sun H, Zhong N, Wan W, Wei H, Xiao J (2019) Clinical significance of traditional clinical parameters and inflammatory biomarkers for the prognosis of patients with spinal chondrosarcoma: a retrospective study of 150 patients in a single center. Eur Spine J 28:1468–1479. https://doi.org/10.1007/s00586-019-05993-4

Article  PubMed  Google Scholar 

Song K, Lin K, Kang H, Dong Y, Guan H, Li F (2020) Primary tumor resection prolongs survival in spinal chondrosarcoma patients with distant metastasis. Spine 45:E1661–E1668. https://doi.org/10.1097/BRS.0000000000003694

Article  PubMed  Google Scholar 

Nguyen MT, Jiang Y-Q, Li X-L, Dong J (2019) Risk factors for incidence and prognosis in chondrosarcoma patients with pulmonary metastasis at initial diagnosis. Med Sci Monit 25:10136–10153. https://doi.org/10.12659/MSM.919184

Article  PubMed  PubMed Central  Google Scholar 

Lin PP, Alfawareh MD, Takeuchi A, Moon BS, Lewis VO (2012) Sixty percent 10-year survival of patients with chondrosarcoma after local recurrence. Clin Orthop Relat Res 470:670–676. https://doi.org/10.1007/s11999-011-2059-8

Article  PubMed  Google Scholar 

Choi JH, Ro JY (2021) The 2020 WHO classification of tumors of bone: an updated review. Adv Anat Pathol 28:119–138. https://doi.org/10.1097/PAP.0000000000000293

Article  PubMed  Google Scholar 

Denu RA, Yang RK, Lazar AJ, Patel SS, Lewis VO, Roszik J, Livingston JA, Wang W-L, Shaw KR, Ratan R, Zarzour MA, Bird J, Raza S, Akdemir KC, Rodon Ahnert J, Subbiah V, Patel S, Conley AP (2023) Clinico-genomic profiling of conventional and dedifferentiated chondrosarcomas reveals TP53 mutation to be associated with worse outcomes. Clin Cancer Res 29:4844–4852. https://doi.org/10.1158/1078-0432.CCR-23-1703

Article  PubMed  Google Scholar 

Song K, Lin K, Guan H, Li F (2020) Conditional survival analysis for spinal chondrosarcoma patients after surgical resection. Spine 45:1110–1117. https://doi.org/10.1097/BRS.0000000000003494

Article  PubMed  Google Scholar 

Nunna RS, Patel S, Patil SN, Ansari D, Burch TG, Mehta AI, Chapman J, Oskouian RJ (2021) Incidence, management, and outcomes of adult patients with spinal chondrosarcoma in the united states. World Neurosurg 149:e316–e328. https://doi.org/10.1016/j.wneu.2021.02.030

Article  PubMed  Google Scholar 

van Maldegem A, Conley AP, Rutkowski P, Patel SR, Lugowska I, Desar IME, Bovée JVMG, Gelderblom H (2019) Outcome of first-line systemic treatment for unresectable conventional, dedifferentiated, mesenchymal, and clear cell chondrosarcoma. Oncologist 24:110–116. https://doi.org/10.1634/theoncologist.2017-0574

Article  PubMed  Google Scholar 

Fromm J, Klein A, Baur-Melnyk A, Knösel T, Lindner L, Birkenmaier C, Roeder F, Jansson V, Dürr HR (2018) Survival and prognostic factors in conventional central chondrosarcoma. BMC Cancer 18:849. https://doi.org/10.1186/s12885-018-4741-7

Article  PubMed  PubMed Central  Google Scholar 

Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, Casanova J, Esler C, Ferrari S, Funovics PT, Gerrand C, Grimer R, Gronchi A, Haffner N, Hecker-Nolting S, Höller S, Jeys L, Jutte P, Leithner A, San-Julian M, Thorkildsen J, Vincenzi B, Windhager R, Whelan J (2015) Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A european musculoskeletal oncology society study. Eur J Cancer 51:374–381. https://doi.org/10.1016/j.ejca.2014.11.007

Article  PubMed  Google Scholar 

Kostine M, Cleven AH, de Miranda NFCC, Italiano A, Cleton-Jansen A-M, Bovée JVMG (2016) Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Mod Pathol 29:1028–1037. https://doi.org/10.1038/modpathol.2016.108

Article  PubMed  Google Scholar 

Arshi A, Sharim J, Park DY, Park HY, Bernthal NM, Yazdanshenas H, Shamie AN (2017) Chondrosarcoma of the osseous spine: an analysis of epidemiology, patient outcomes, and prognostic factors using the SEER registry from 1973 to 2012. Spine 42:644–652. https://doi.org/10.1097/BRS.0000000000001870

Article  PubMed  PubMed Central  Google Scholar 

Tuval A, Strandgren C, Heldin A, Palomar-Siles M, Wiman KG (2024) Pharmacological reactivation of p53 in the era of precision anticancer medicine. Nat Rev Clin Oncol 21:106–120. https://doi.org/10.1038/s41571-023-00842-2

Article  PubMed  Google Scholar 

Amer KM, Munn M, Congiusta D, Abraham JA, Basu Mallick A (2020) Survival and prognosis of chondrosarcoma subtypes: SEER database analysis. J Orthop Res 38:311–319. https://doi.org/10.1002/jor.24463

Article  PubMed  Google Scholar 

El Beaino M, Hoda ST, Eldeib AJ, Masrouha K (2023) Dedifferentiated chondrosarcoma: diagnostic controversies and emerging therapeutic targets. Curr Oncol Rep 25:1117–1126. https://doi.org/10.1007/s11912-023-01441-1

Article  PubMed  Google Scholar 

Strach MC, Grimison PS, Hong A, Boyle R, Stalley P, Karim R, Connolly EA, Bae S, Desai J, Crowe P, Singhal N, Bhadri VA (2023) Mesenchymal chondrosarcoma: an australian multi-centre cohort study. Cancer Med 12:368–378. https://doi.org/10.1002/cam4.4849

Article  PubMed  Google Scholar 

Ma X, Meng G, Wang K, Li D, Wang L, Li H, Zhang J, Zhang L, Wu Z (2019) The differences between intracranial mesenchymal chondrosarcoma and conventional chondrosarcoma in clinical features and outcomes. World Neurosurgery 122:e1078–e1082. https://doi.org/10.1016/j.wneu.2018.10.230

Article  PubMed  Google Scholar 

Behling F, Fodi C, Skardelly M, Paulsen F, Tabatabai G, Honegger J, Tatagiba M, Schittenhelm J (2023) The prognostic role of the immunohistochemical expression of S100 in meningiomas. J Cancer Res Clin Oncol 149:2975–2985. https://doi.org/10.1007/s00432-022-04186-9

Article  PubMed  Google Scholar 

Wang J, Wang W, Wang L, Tang T, Hu C, Song X (2022) The prognostic value of S-100 protein and Ki-67 index in olfactory neuroblastoma. Jpn J Clin Oncol 52:1008–1013. https://doi.org/10.1093/jjco/hyac094

Article  PubMed  Google Scholar 

Wang T, Yin H, Han S, Yang X, Wang J, Huang Q, Yan W, Zhou W, Xiao J (2015) Malignant peripheral nerve sheath tumor (MPNST) in the spine: a retrospective analysis of clinical and molecular prognostic factors. J Neurooncol 122:349–355. https://doi.org/10.1007/s11060-015-1721-5

Article  PubMed  Google Scholar 

Kasago IS, Chatila WK, Lezcano CM, Febres-Aldana CA, Schultz N, Vanderbilt C, Dogan S, Bartlett EK, D’Angelo SP, Tap WD, Singer S, Ladanyi M, Shoushtari AN, Busam KJ, Hameed M (2023) Undifferentiated and dedifferentiated metastatic melanomas masquerading as soft tissue sarcomas: mutational signature analysis and immunotherapy response. Mod Pathol 36:100165. https://doi.org/10.1016/j.modpat.2023.100165

Article  PubMed  PubMed Central  Google Scholar 

Han M, Kakar M, Li W, Iqbal I, Hu X, Liu Y, Tang Q, Sun L, Shakir Y, Liu T (2024) Targeting MDM2-p53 interaction in glioblastoma: transcriptomic analysis and peptide-based inhibition strategy. Bioorg Chem 150:107620. https://doi.org/10.1016/j.bioorg.2024.107620